These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 16638639)
1. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. Vilaine JP Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639 [TBL] [Abstract][Full Text] [Related]
2. [The discovery of the selective If current inhibitor ivabradine (Procoralan): a new therapeutic approach to ischemic heart disease]. Vilaine JP Med Sci (Paris); 2006 Jan; 22(1):87-94. PubMed ID: 16386229 [TBL] [Abstract][Full Text] [Related]
3. Ivabradine: an intelligent drug for the treatment of ischemic heart disease. Riccioni G Molecules; 2012 Nov; 17(11):13592-604. PubMed ID: 23159921 [TBL] [Abstract][Full Text] [Related]
4. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. Monnet X; Ghaleh B; Colin P; de Curzon OP; Giudicelli JF; Berdeaux A J Pharmacol Exp Ther; 2001 Dec; 299(3):1133-9. PubMed ID: 11714904 [TBL] [Abstract][Full Text] [Related]
5. Anti-ischaemic effect of ivabradine. Ferrari R; Cargnoni A; Ceconi C Pharmacol Res; 2006 May; 53(5):435-9. PubMed ID: 16644235 [TBL] [Abstract][Full Text] [Related]
6. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. DiFrancesco D; Camm JA Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560 [TBL] [Abstract][Full Text] [Related]
7. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. Vilaine JP; Bidouard JP; Lesage L; Reure H; Péglion JL J Cardiovasc Pharmacol; 2003 Nov; 42(5):688-96. PubMed ID: 14576519 [TBL] [Abstract][Full Text] [Related]
8. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Mulder P; Barbier S; Chagraoui A; Richard V; Henry JP; Lallemand F; Renet S; Lerebours G; Mahlberg-Gaudin F; Thuillez C Circulation; 2004 Apr; 109(13):1674-9. PubMed ID: 14981003 [TBL] [Abstract][Full Text] [Related]
9. Ivabradine -- the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Sulfi S; Timmis AD Int J Clin Pract; 2006 Feb; 60(2):222-8. PubMed ID: 16451297 [TBL] [Abstract][Full Text] [Related]
11. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. Ferrari R; Ceconi C Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041 [TBL] [Abstract][Full Text] [Related]
12. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction. Perry CM Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944 [TBL] [Abstract][Full Text] [Related]
13. [A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina]. Kobalava ZD; Shavarov AA; Kiyakbaev GK Kardiologiia; 2017 Mar; 57(3):68-74. PubMed ID: 28762939 [TBL] [Abstract][Full Text] [Related]
14. [Ivabradine, an I(f) current inhibitor--new treatment options in coronary heart disease]. Mach F Rev Med Suisse; 2009 May; 5(205):1168-70, 1172-3. PubMed ID: 19517748 [TBL] [Abstract][Full Text] [Related]
15. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction. Rosano GM; Vitale C; Volterrani M Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895 [TBL] [Abstract][Full Text] [Related]
16. Ivabradine: cardiovascular effects. Rognoni A; Bertolazzi M; Macciò S; Rognoni G Recent Pat Cardiovasc Drug Discov; 2009 Jan; 4(1):61-6. PubMed ID: 19149708 [TBL] [Abstract][Full Text] [Related]
17. Preclinical results with I(f) current inhibition by ivabradine. Berdeaux A Drugs; 2007; 67 Suppl 2():25-33. PubMed ID: 17999561 [TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Fox K; Ferrari R; Tendera M; Steg PG; Ford I; Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146 [TBL] [Abstract][Full Text] [Related]
19. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Tardif JC Drugs Today (Barc); 2008 Mar; 44(3):171-81. PubMed ID: 18536779 [TBL] [Abstract][Full Text] [Related]
20. [New pharmacological approaches to ischemic heart disease]. Raddino R; Della Pina P; Gorga E; Brambilla G; Regazzoni V; Gavazzoni M; Dei Cas L G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):50S-54S. PubMed ID: 23096376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]